Business Wire

JAB-HOLDING-COMPANY

Share
JAB’s Pinnacle Pet Group Expands Through Acquisition of Veterfina’s European Pet Insurance Business

JAB Holding Company (“JAB”) is pleased to announce the signing of a definitive agreement through which Pinnacle Pet Group (“PPG”) will acquire 100% of the shares in Veterfina Verzekeringsmaatschappij N.V. and its European subsidiaries (“Veterfina”), one of the largest and fastest growing pet insurance businesses headquartered in the Netherlands. The transaction is expected to close in Q4 2022, subject to customary closing conditions, including regulatory approvals. Financial terms of the agreement were not disclosed.

As part of the agreement, founder and CEO Nico Schuurbiers will continue in his current role and maintain a minority stake in PPG alongside co-founder Han de Groot. PPG will provide significant growth equity to accelerate the European expansion and development of Veterfina’s multi-brand and omni-channel strategy. This will include the introduction of FIGO, JAB’s D2C pet insurance brand and digital platform, in select European markets.

We share JAB’s ambitions for the pet insurance market and are highly energised by the opportunity to work with the rest of the group ,” said Mr. Schuurbiers. “We have achieved great success in the Dutch market, but with the support of JAB’s pet insurance ecosystem, we can accelerate our geographic expansion and digital offering, starting in Belgium this year .”

Today’s news follows JAB’s recently announced acquisition of AGILA Tierversicherung AG (“AGILA”), the German market leader in pet insurance, from the WERTGARANTIE Group, and the acquisition of Cardif Pinnacle from BNP Paribas Cardif in October 2021.

We continue to see significant growth opportunities in the European pet insurance and pet healthcare sector ,” said Joachim Creus, Managing Partner at JAB and Chairman of the JAB pet insurance platform. “Veterfina has a strong customer base and excellent product offerings in the Netherlands with a growing pan-European offering, which we will build on as we look to expand into new markets such as Belgium and France .”

We are thrilled to welcome Veterfina and its whole team to the Pinnacle Pet Group ,” said Dirk Beeckman, CEO of JAB pet insurance platform and PPG. “Our ambition is to create the leading pet insurance platform globally, with the group benefiting from the knowledge and capabilities from each addition.

About JAB

JAB Holding Company invests in consumer-focused industries with attractive long-term dynamics, including strong growth prospects, attractive margin and cash flow characteristics, and proven resiliency. Together with JAB Consumer Partners, JAB Holding Company is the largest shareholder of Keurig Dr Pepper, a leader in the North American beverage market and Krispy Kreme Doughnut, a global leader in doughnuts and other premium-quality sweet treats, and has controlling stakes in JDE Peet’s, the largest pure-play fast-moving consumer goods coffee company in the world; NVA, one of the world’s largest animal care services platforms; Independence Pet Group, a fully integrated leading North American pet insurance platform; Pinnacle Pet Group, a fully integrated leading pan-European pet insurance platform; Panera Brands, one of the world’s largest fast casual restaurant companies, which includes Panera Bread, Caribou Coffee and Einstein Bagels; Pret A Manger, a leading company in the ready-to-eat food market; and Espresso House, the largest branded coffee shop chain in Scandinavia. JAB Holding Company is also the largest shareholder in Coty Inc., a global leader in beauty, and owns luxury goods company Bally.

About Pinnacle Pet Group

Pinnacle Pet Group (“PPG” or “the Group”) is a pan-European, fully integrated pet insurance & health services platform indirectly owned by JAB Holding Company. PPG’s ambition is to create the leading pet insurance and health services platform globally, outside North America. The Group offers a complete range of pet insurance products and services, catering to both animal owners, distribution partners, breeders, shelters, and veterinarians. The Group was established in 2021 through a joint venture with BNP Paribas Cardif, which transferred the majority ownership of Cardif Pinnacle to JAB. As the insurance subsidiary of BNP Paribas, BNP Paribas Cardif is the world leader in bancassurance partnerships and creditor insurance. Within the UK, Cardif Pinnacle developed products and services focused on the Pet Insurance market. In July 2022, JAB and PPG announced the acquisition of AGILA Tierversicherung AG (“AGILA”), the German market leader in pet insurance, from the WERTGARANTIE Group. AGILA AG is based in Hannover and was founded in 1994 as a subsidiary of WERTGARANTIE. AGILA is the market leader in animal health insurance for dogs and cats in Germany and Austria.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alpega Group Completes Leadership Succession Plan Appointing Daniel Cohen New CEO8.1.2026 10:03:00 CET | Press release

Alpega Group, a leading pan-European provider of an end-to-end transportation and logistics platform, today announced a planned leadership transition. After a successful tenure as Chief Executive Officer, Todd DeLaughter will be retiring, stepping down from his role and transitioning to a Board Advisor role for the company. The Board of Directors has appointed Daniel Cohen as the incoming CEO, effective January 1st, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108528648/en/ Daniel Cohen, CEO Alpega Daniel Cohen brings three decades of experience leading B2B SaaS businesses through periods of change, scale, and value realization. Most recently, as CEO of PayU, he led a full financial, operational, and cultural transformation returning the business to sustained profitable growth. He subsequently steered the company through a highly complex, multi-jurisdictional process that culminated in the successful sale to Rapyd

FPT Named Sitecore’s First Global Partner Under Global Elite Reseller Program8.1.2026 09:00:00 CET | Press release

Global IT Corporation FPT announced its appointment as the inaugural Global Elite Reseller under a new initiative from Sitecore that expands upon its successful Global Reseller Program. The Global Elite Reseller Program follows the launch of SitecoreAI, the next-generation digital experience platform that puts artificial intelligence at the center of marketing, unifying content, data, and personalization in one composable platform so organizations can reach, engage, and serve their audience across digital channels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107425261/en/ Representatives from FPT and Sitecore at the Global Elite Reseller signing ceremony. Under the agreement, FPT will hold exclusive reseller rights in Vietnam and non-exclusive rights across select markets in Asia and the Middle East, taking SitecoreAI to market and showing how it helps teams plan, create, and optimize digital experiences using AI as cu

Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release

Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin

4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release

FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F

Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release

The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye